20/06/2020
Coronavirus pandemic | Glenmark launches COVID-19 drug FabiFlu after DCGI nod
FabiFlu is the first oral Favipiravir-approved medication for the treatment of COVID-19, the company said in a statement.
PTI
Glenmark Pharmaceuticals on Saturday said it has launched antiviral drug Favipiravir, under the brand name FabiFlu, for the treatment of patients with mild to moderate COVID-19. The Mumbai-based drug firm had on Friday received manufacturing and marketing approval from the Drugs Controller General of India (DCGI).
FabiFlu is the first oral Favipiravir-approved medication for the treatment of COVID-19, the company said in a statement.
Advertisement
Powered By PLAYSTREAM
Track this blog for LIVE updates on coronavirus pandemic
CLOSE
"This approval comes at a time when cases in India are spiralling like never before, putting a tremendous pressure on our healthcare system," Glenmark Pharmaceuticals Chairman and Managing Director Glenn Saldanha said.
RELATED NEWS
Centre's employment scheme for migrant workers to give new base to rural development: Yogi Adityanath
AP SSC exams 2020 | Andhra Pradesh Class 10 exams cancelled, says Education Minister A Suresh
Delhi LG rolls back order mandating 5-day institutional quarantine for all COVID-19 patients
The company hopes that the availability of an effective treatment such as FabiFlu will considerably help assuage this pressure, and offer patients in India a much needed and timely therapy option, he added.
